Amarin Corp Plc (AMRN)

[Number sleven]

HDG, I agree that an appropriate use of a PA could insulate insurance companies from obvious infringment. I don't know if the lack of a PA would provide protection.
Hikma is not an impossible position. That is why the magistrate recommend that the case proceed. Take a look at the ruling in GSK v Teva. This ruling blurred the law on infringment. The legal issue that I see is the validity of the carve out. How do you separate VHTG from CVD. I don't see them as two distinct and separate indications. The FDA position on off label prescriptions has nothing to do with patent law.
Sleven,